DrugPatentWatch Database Preview
OLUMIANT Drug Profile
Email this page to a colleague
When do Olumiant patents expire, and when can generic versions of Olumiant launch?
Olumiant is a drug marketed by Eli Lilly And Co and is included in one NDA. There are two patents protecting this drug.
This drug has fifty-four patent family members in forty-two countries.
The generic ingredient in OLUMIANT is baricitinib. One supplier is listed for this compound. Additional details are available on the baricitinib profile page.
DrugPatentWatch® Generic Entry Outlook for Olumiant
Olumiant will be eligible for patent challenges on May 31, 2022. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be June 8, 2030. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
Summary for OLUMIANT
| International Patents: | 54 |
| US Patents: | 2 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 94 |
| Clinical Trials: | 6 |
| Patent Applications: | 936 |
| Drug Prices: | Drug price information for OLUMIANT |
| What excipients (inactive ingredients) are in OLUMIANT? | OLUMIANT excipients list |
| DailyMed Link: | OLUMIANT at DailyMed |
DrugPatentWatch® Estimated Generic Entry Opportunity Date for OLUMIANT
Generic Entry Date for OLUMIANT*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
TABLET;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for OLUMIANT
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Institut National de la Santé Et de la Recherche Médicale, France | Phase 2/Phase 3 |
| Oslo University Hospital | Phase 2/Phase 3 |
| Epidemiological and Clinical Research Information Network | Phase 2/Phase 3 |
Pharmacology for OLUMIANT
| Drug Class | Janus Kinase Inhibitor |
| Mechanism of Action | Janus Kinase Inhibitors |
ATC Classes for OLUMIANT
US Patents and Regulatory Information for OLUMIANT
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Eli Lilly And Co | OLUMIANT | baricitinib | TABLET;ORAL | 207924-002 | Oct 8, 2019 | RX | Yes | No | Try Before You Buy | Try Before You Buy | Try Before You Buy | ||||
| Eli Lilly And Co | OLUMIANT | baricitinib | TABLET;ORAL | 207924-001 | May 31, 2018 | RX | Yes | Yes | Try Before You Buy | Try Before You Buy | Y | Y | Try Before You Buy | ||
| Eli Lilly And Co | OLUMIANT | baricitinib | TABLET;ORAL | 207924-002 | Oct 8, 2019 | RX | Yes | No | Try Before You Buy | Try Before You Buy | Y | Y | Try Before You Buy | ||
| Eli Lilly And Co | OLUMIANT | baricitinib | TABLET;ORAL | 207924-001 | May 31, 2018 | RX | Yes | Yes | Try Before You Buy | Try Before You Buy | Try Before You Buy | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for OLUMIANT
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Spain | 2602577 | Try Before You Buy |
| Colombia | 6290658 | Try Before You Buy |
| Morocco | 32219 | Try Before You Buy |
| Eurasian Patent Organization | 017218 | Try Before You Buy |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for OLUMIANT
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2288610 | 17C0005 | France | Try Before You Buy | PRODUCT NAME: BARICITINIB; REGISTRATION NO/DATE: EU/1/16/1170 20170215 |
| 2288610 | 132017000078559 | Italy | Try Before You Buy | PRODUCT NAME: BARICITINIB E I SUOI SALI FARMACEUTICAMENTE ACCETTABILI(OLUMIANT); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/16/1170, 20170215 |
| 2288610 | LUC00027 | Luxembourg | Try Before You Buy | PRODUCT NAME: BARICITINIB ET SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; AUTHORISATION NUMBER AND DATE: EU/1/16/1170 20170215 |
| 2288610 | CA 2017 00032 | Denmark | Try Before You Buy | PRODUCT NAME: BARICITINIB AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REG. NO/DATE: EU/1 /16/1170 20170215 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
